Review article: management of chronic hepatitis C in patients with contraindications to anti-viral therapy
- 26 November 2013
- journal article
- review article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 39 (2), 148-162
- https://doi.org/10.1111/apt.12562
Abstract
There are patients with chronic hepatitis C who are not eligible for the current interferon‐based therapies or refuse to be treated due to secondary effects.This publication has 100 references indexed in Scilit:
- Effect of Silymarin (Milk Thistle) on Liver Disease in Patients With Chronic Hepatitis C Unsuccessfully Treated With Interferon TherapyJAMA, 2012
- Naringenin inhibits the assembly and long-term production of infectious hepatitis C virus particles through a PPAR-mediated mechanismJournal of Hepatology, 2011
- Identification of hepatoprotective flavonolignans from silymarinProceedings of the National Academy of Sciences of the United States of America, 2010
- Multiple effects of silymarin on the hepatitis C virus lifecycleJournal of Hepatology, 2010
- Increased caffeine consumption is associated with reduced hepatic fibrosisJournal of Hepatology, 2009
- Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitisJournal of Hepatology, 2009
- Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis CJournal of Hepatology, 2009
- Fructose consumption as a risk factor for non-alcoholic fatty liver diseaseJournal of Hepatology, 2008
- AM3, a natural glycoconjugate, induces the functional maturation of human dendritic cellsBritish Journal of Pharmacology, 2008
- The effect of iron depletion on chronic hepatitis C virus infectionHepatology International, 2008